Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

181.08USD
17 Feb 2017
Change (% chg)

$2.38 (+1.33%)
Prev Close
$178.70
Open
$179.94
Day's High
$181.81
Day's Low
$179.02
Volume
424,063
Avg. Vol
415,380
52-wk High
$209.20
52-wk Low
$150.14

Latest Key Developments (Source: Significant Developments)

Third Point LLC takes share stake in JPMorgan, Bank of America - SEC Filing
Friday, 10 Feb 2017 04:44pm EST 

Third Point Llc : Third Point Llc dissolves share stake in Allergan Plc - SEC Filing . Third Point Llc takes share stake of 1.0 million shares in Anthem Inc . Third Point Llc takes share stake of 3.0 million shares in Conagra Brands Inc . Third Point Llc takes share stake of 1.4 million shares in Honeywell International Inc . Third Point Llc takes share stake of 17.5 million shares in Bank of America . Third Point Llc dissolves share stake in Liberty Global Plc . Third Point Llc dissolves share stake in Shire Plc . Third Point Llc takes share stake of 5.3 million shares in JPMorgan Chase & Co .Third Point Llc - change in holdings are as of Dec 31, 2016 and compared with the previous quarter ended as of Sept 30, 2016.  Full Article

Shire Plc responds to U.S. Federal Trade Commission civil action
Tuesday, 7 Feb 2017 03:42pm EST 

Shire Plc : Shire plc says responds to u.s. Federal trade commission civil action . Shire plc -acknowledges decision by u.s. Federal trade commission to file a civil action against one of its subsidiaries, shire viropharma . Shire plc -decision by u.s. Ftc related to citizen petition submissions viropharma filed regarding one of its products, vancocin .Shire plc says "company played no role in viropharma's challenged petitioning, which took place between 2006 and 2012".  Full Article

U.S FDA acknowledges receipt of Shire's ADHD drug application
Thursday, 19 Jan 2017 07:04am EST 

Shire Plc : U.S. FDA acknowledges receipt of Shire's new drug application for SHP465 for ADHD . fda has acknowledged receipt of class 2 resubmission of a new drug application (nda) for shp465, a long-acting, triple-bead, mixed amphetamine salts formulation . Shp465 is being evaluated as a potential once-daily treatment for attention-deficit/hyperactivity disorder . FDA is expected to provide a decision on or around june 20, 2017, designated prescription drug user fee act (PDUFA) action date .Protection for shire's ADHD franchise extends to 2029.  Full Article

Momenta provides year-end 2016 corporate update
Friday, 6 Jan 2017 08:00am EST 

Momenta Pharmaceuticals Inc : Momenta provides year-end 2016 corporate update . Momenta Pharmaceuticals Inc - reiterated its non-gaap operating expense guidance of approximately $40 - $45 million for Q4 of 2016 . Momenta Pharmaceuticals Inc - expects to report approximately $350.0 million of cash, cash equivalents and marketable securities at December 31, 2016 .Momenta Pharmaceuticals Inc - currently assessing U.S. Gaap accounting treatment for shire and csl agreements.  Full Article

RaNa acquires Shire's industry leading messenger RNA platform
Wednesday, 4 Jan 2017 07:30am EST 

Shire Plc : RaNa acquires Shire's industry leading messenger RNA platform . RaNa Therapeutics announces acquisition of MRT platform, an MRNA therapy platform, developed by subsidiaries of Shire .RaNa Therapeutics says Shire to receive equity stake in RaNa and is eligible for future milestones and royalties on products developed with technology.  Full Article

Shire says topline results of Phase 3 investigational study of Vonvendi meets primary endpoint
Friday, 2 Dec 2016 11:02am EST 

Shire Plc : Topline results of Phase 3 investigational study of Vonvendi™ [von Willebrand factor (recombinant)] meets primary endpoint effectively controlling bleeding and blood loss during surgical procedures . Vonvendi is also being studied for prophylaxis and pediatric indications . Results of Phase 3 investigational study of Vonvendi Willebrand factor meets primary endpoint .Results from Phase 3 investigational study to be used to support filing for regulatory approvals in Europe in 2017 and in other markets globally.  Full Article

Coherus Biosciences regains development and commercial rights to CHS-0214 from Shire
Tuesday, 27 Sep 2016 08:00am EDT 

Coherus Biosciences Inc. : Says has regained from shire plc all development and commercial rights previously licensed for chs-0214 etanercept . Coherus Biosciences regains development and commercial rights to CHS 0214 from Shire . As result of termination agreement with Shire, co expects to recognize $162.6 million as collaboration and license revenues in 2016 . CHS-0214 etanercept is a biosimilar candidate to enbrel for Europe, Canada, Brazil, Middle East and other territories .Remain on track for submission of a CHS-0214 marketing authorization application to european medicines agency in Q4 of 2016.  Full Article

Mmenta Pharmaceuticals to regain global development and commercialization rights to M923
Tuesday, 27 Sep 2016 08:00am EDT 

Momenta Pharmaceuticals Inc. : Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire . Agreement to terminate 12 months following notice; Shire will continue to be obligated to fund M923 program till termination . Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire .Co expects top-line results of current phase 3 trial of M923 in late 2016.  Full Article

Shire says prescription eye drop, xiidra 5% is now available in U.S.
Monday, 29 Aug 2016 10:47am EDT 

Shire Plc :Prescription eye drop, xiidra 5% is now available in the u.s..  Full Article

Shire launches Von Willebrand disease drug in the U.S
Tuesday, 9 Aug 2016 07:14am EDT 

Shire Plc :Announced U.S. launch of Vonvendi [von willebrand factor (recombinant)], only recombinant treatment for adults living with Von Willebrand Disease.  Full Article

More From Around the Web

Pharma group Shire produces top-of-the-range earnings

LONDON Pharmaceuticals group Shire on Thursday said it was extremely optimistic about long-term growth after reporting a 12 percent rise in earnings for the past year in which it made its largest ever acquisition.